When exposed to opioids before birth, some newborns experience painful withdrawal, including frantic breathing, racing heart rates, constant crying, and tremors. Thanks to grants from the National Institute on Drug Abuse (NIDA), the FDA is currently reviewing our De Novo submission for the Prapela bassinet pad to treat newborns with neonatal opioid withdrawal syndrome or NOWS.
Apnea of Prematurity (AOP)
When preterm newborns stop breathing for 20 seconds or more, caffeine is prescribed more than any other treatment. Even after caffeine, most newborns continue to experience apneas several times a day. Prapela is pursuing approval for our pad to be used with caffeine to further reduce apnea episodes and the risk of low oxygen to vital organs.
Respiratory Syncytial Virus (RSV)
A severly contagious virus, respiratory syncytial virus (RSV) responsible for the majority of Emergency Room visits for newborns 6 months old and younger. Most newborns treated for RSV require respiratory support. A study, soon to be published, found improved oxygen uptake in ventilated newborns while lying on a pad with Prapela's vibration.